share_log

HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification.

HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification.

HUTCHMED的股票在公司宣佈已完成對MET擴增的胃癌患者進行Savolitinib二期試驗的註冊階段的招募後上漲。
Benzinga ·  04/23 02:15

HUTCHMED Shares Are Trading Higher After the Company Announced It Completed Enrollment of the Registration Phase of Its Phase II Trial of Savolitinib in Gastric Cancer Patients With MET Amplification.

HUTCHMED的股票在公司宣佈已完成對MET擴增的胃癌患者進行Savolitinib二期試驗的註冊階段的招募後上漲。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論